Lete Uspomene - Search News

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review [2]; primary efficacy endpoint ...

Cure Today

T-Cell Therapy With Lete-Cel Demonstrates Efficacy in Sarcoma Subtypes

Letetresgene autoleucel (lete-cel) showed a 42% response rate in a phase 2 trial for synovial sarcoma and myxoid/round cell liposarcoma. The trial included 64 patients, with 41% response in synovial ...

Yahoo Finance

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

Yahoo

Exclusive: Deal or No Deal Island Season 2’s Alexis Lete on Why She Feels “Betrayed” and Life Lessons She Learned From the Game

Deal or No Deal Island Season 2 was down to the final three players. Courtney “CK” Kim, David Genat, and Alexis Lete all took part in the final excursion. Seeing familiar faces from the game either ...

Nasdaq

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...

WAVE3

Vicki Lete: Moore principal to be removed at end of contract

LOUISVILLE, KY (WAVE) – Decision makers at Moore Traditional School decided not to appeal Vicki Lete's removal as Principal of the school. A report by the Kentucky Department of Education found Lete ...

Nasdaq

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

The Courier-Journal

New Albany's Lete a volleyball late bloomer

New Albany senior middle hitter Alexis Lete was a volleyball late bloomer who didn't develop into a star until high school. She's making up for lost time. Lete was a member of the Junior All-Stars ...

Morningstar

US WorldMeds Completes Acquisition of Adaptimmune's Cell-Therapy Portfolio; Ensures Continued Patient Access to Tecelra and Advances Development of lete-cel

LOUISVILLE, Ky., Aug. 4, 2025 /PRNewswire/ -- US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc's (Adaptimmune) cell–therapy ...